Business Combinations (ViroPharrma) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended				0 Months Ended	3 Months Ended		0 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Jan. 24, 2014 Viropharma	Mar. 31, 2014 Viropharma	Mar. 31, 2013 Viropharma	Jan. 24, 2014 Viropharma Minimum	Jan. 24, 2014 Viropharma Maximum	Jan. 24, 2014 Viropharma Currently Marketed Products	Jan. 24, 2014 Viropharma IPR&D
Business Acquisition [Line Items]
Percentage of voting interests acquired					100.00%
Cash consideration paid					$ 3,997.0
Current assets:
Cash and cash equivalents					232.6
Short term investments					57.8
Accounts receivable					52.2
Inventories					203.5
Deferred tax assets					100.2
Purchased call option					346.7
Other current assets					42.5
Total current assets					1,035.5
Non-current assets:
Property, plant and equipment					24.7
Goodwill	2,161.2	522.8	624.6	644.5	1,536.6
Other intangible assets, net										2,320.0	530.0
Other non-current assets					11.6
Total assets					5,458.4
Current liabilities:
Accounts payable and other current liabilities					116.6
Convertible bond					551.4
Non-current liabilities:
Deferred tax liabilities					695.9
Other non-current liabilities					97.5
Total liabilities					1,461.4
Fair value of identified assets acquired and liabilities assumed					3,997.0
Pro Forma Information
Post acquisition revenues included in consolidated statement of income						92.8
Post acquisition pre-tax losses included in consolidated statement of income						59.2
Post acquisition amortization of intangible assets included in consolidated statement of income						23.3
Post acquisition unwind of inventory fair value adjustment included in consolidated statement of income	38.8	0				38.8
Post acquisition integration costs included in consolidated statement of income						25.8
Weighted average amortization period of acquired amortizable intangible assets					21 years
Discount rate used in determining fair value of acquired in process research and development, low rate					9.50%
Discount rate used in determining fair value of acquired in process research and development, high rate					10.00%
Integration and acquisition costs	$ 6.6	$ 4.1				$ 65.8	$ 0
Estimated useful life of intangible assets								3 years	23 years